Series A
$29m
RAGE Biotech raises $29 million for new lung disease treatment
Melbourne biotech RAGE Biotech has raised a $29 million Series A, with IP Group Australia and Hostplus leading, to fund human trials of its lung disease therapy; new executives were appointed.
Also Startup Daily